Skip to main content
. 2017 Jul 24;28(5):e74. doi: 10.3802/jgo.2017.28.e74

Fig. 7.

Fig. 7

Anti-PD-1 monoclonal antibody BGB-A317+PARPi BGB-290 in advanced solid tumors design schema.

BID, twice a day; ECOG, Eastern Cooperative Oncology Group; MTD, maximum tolerated dose; PD-1, programmed death-1; PO, per os; PS, performance score; Q, every; RP2D, recommended phase II dose.